<- Go Home

VolitionRx Limited

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.

Market Cap

$39.4M

Volume

204.6K

Cash and Equivalents

$2.3M

EBITDA

-$22.4M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$1.3M

Profit Margin

100.00%

52 Week High

$0.94

52 Week Low

$0.33

Dividend

N/A

Price / Book Value

-1.08

Price / Earnings

-1.35

Price / Tangible Book Value

-1.07

Enterprise Value

$46.9M

Enterprise Value / EBITDA

-2.11

Operating Income

-$23.5M

Return on Equity

83.99%

Return on Assets

-134.74

Cash and Short Term Investments

$2.3M

Debt

$10.9M

Equity

-$33.1M

Revenue

$1.3M

Unlevered FCF

-$33.5M

Sector

Health Care Equipment and Supplies

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches